Stemline Therapeutics is a new company record. Its research profile isn't ready yet.
stemline.comCrawled Oct 30, 2026
Anti-leukemia efficacy and mechanisms of action of SL-101, a novel anti-CD123 antibody-conjugate in acute myeloid leukemia. ASH 2014. Poster
Elacestrant, an oral selective estrogen receptor degrader, is compared to endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer.
Interim results from an ongoing Phase 1 trial of SL-801, a novel XPO-1 inhibitor, were presented at ESMO 2017.
SL-101, a monoclonal antibody-conjugate targeting CD123, demonstrates preclinical anti-tumor activity against Hodgkin’s lymphoma.
A pilot study examines peptide-based vaccines combined with poly ICLC in patients with WHO grade 2 low-grade glioma.
Interim results from a Phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors were presented at ASCO.
Peptide vaccine therapy for childhood gliomas: interim results of a pilot study. AACR 2012. Abstract | Poster
A Phase 2 trial tests SL-701, an immunotherapy of synthetic short peptides against GBM targets IL-13Rα2, EphA2, and Survivin.
October 12, 2017 Corporate Presentation – October 2017 VIEW PRESENTATION
September 26, 2017 Ladenburg Thalmann 2017 Healthcare Conference LISTEN TO THE WEBCAST
Dr. Bergstein is Chief Executive Officer and Founder of Stemline Therapeutics. Dr. Bergstein has managed the company’s evolution from early-stage research and development to the FDA approval of its lead product, ELZONRIS.
Stemline Therapeutics, a part of the Menarini Group, is focused on the development and commercialization of novel oncology therapeutics.
The company develops, manufactures, and commercializes drugs, offering partners integrated solutions and seeking drug candidates for licensing or acquisition.
Please call 1-877-332-7961 to report an adverse event.
Stemline Therapeutics collects and uses personal information through its websites and offline interactions, as outlined in its Privacy Policy.
